[Local application of bFGF and sucralfate during continuous tissue expansion].
OBJECTIVE
To investigate the effect of local application of bFGF and sucralfate during continuous tissue expansion (CTE).


METHODS
CTE combined with local administration of bFGF and sucralfate was used in twelve patients with scar and nasal tip defects. Twenty three expanders were placed in the subcutaneous pockets through intralesion short incisions. Continuous expansion began at 1-3 days after expander implantation. The histomorphological changes and epidermal cell proliferation were observed. The clinical results were investigated.


RESULTS
The average inflation time was 8.9 days. The average interval of the two operations was 13.5 days. The average hospitalization was 28.4 days. The average immediate stretch-back rate of the expanded skin was 25.7%. The clinical results were satisfactory without any complications. Histological examinations showed that the epidermal, granular and spinous layer became thicker. The basal cells increased significantly. The dermis thinned slightly and the collagen fibers became thicker. The elastic fiber regenerated significantly. Fibroblast and capillary density increased obviously. The immunohistochemistry analysis showed that the proliferation of epidemic basal cells was significant postoperatively.


CONCLUSIONS
Local application of exogenous bFGF and sucralfate during CTE was feasible in patients. It could accelerate tissue expansion and improve the quality of expanded skin flap.
Hu
Ya-lan
YL
Department of Plastic Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
Guo
Shu-zhong
SZ
Lu
Kai-hua
KH
Han
Yan
Y
Lei
Yong-hong
YH
Song
Bao-qiang
BQ
Pan
Yong
Y
D002196:Capillaries / Q000033:anatomy & histology; D049109:Cell Proliferation; D003094:Collagen / Q000032:analysis; D020405:Dermis / Q000098:blood supply / Q000473:pathology; D000078404:Epidermal Cells; D005346:Fibroblast Growth Factors / Q000494:pharmacology*; D005347:Fibroblasts / Q000166:cytology; D006801:Humans; D007902:Length of Stay; D009667:Nose Deformities, Acquired / Q000601:surgery*; D013392:Sucralfate / Q000494:pharmacology*; D013524:Surgical Flaps / Q000098:blood supply; D013997:Time Factors; D015626:Tissue Expansion / Q000295:instrumentation / Q000379:methods*; D015625:Tissue Expansion Devices; D016896:Treatment Outcome
D013392:Sucralfate; D005346:Fibroblast Growth Factors; D003094:Collagen